A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer
- Author:
Chang Min KIM
1
;
Kyong Hwa PARK
;
Yun Suk YU
;
Ju Won KIM
;
Jin Young PARK
;
Kyunghee PARK
;
Jong-Han YU
;
Jeong Eon LEE
;
Sung Hoon SIM
;
Bo Kyoung SEO
;
Jin Kyeoung KIM
;
Eun Sook LEE
;
Yeon Hee PARK
;
Sun-Young KONG
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2024;56(4):1113-1125
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Triple-negative breast cancer (TNBC) is a particularly challenging subtype of breast cancer, with a poorer prognosis compared to other subtypes. Unfortunately, unlike luminal-type cancers, there is no validated biomarker to predict the prognosis of patients with early-stage TNBC. Accurate biomarkers are needed to establish effective therapeutic strategies.
Materials and Methods:In this study, we analyzed gene expression profiles of tumor samples from 184 TNBC patients (training cohort, n=76; validation cohort, n=108) using RNA sequencing.
Results:By combining weighted gene expression, we identified a 10-gene signature (DGKH, GADD45B, KLF7, LYST, NR6A1, PYCARD, ROBO1, SLC22A20P, SLC24A3, and SLC45A4) that stratified patients by risk score with high sensitivity (92.31%), specificity (92.06%), and accuracy (92.11%) for invasive disease-free survival. The 10-gene signature was validated in a separate institution cohort and supported by meta-analysis for biological relevance to well-known driving pathways in TNBC. Furthermore, the 10-gene signature was the only independent factor for invasive disease-free survival in multivariate analysis when compared to other potential biomarkers of TNBC molecular subtypes and T-cell receptor β diversity. 10-gene signature also further categorized patients classified as molecular subtypes according to risk scores.
Conclusion:Our novel findings may help address the prognostic challenges in TNBC and the 10-gene signature could serve as a novel biomarker for risk-based patient care.
